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Background: Medicine-related burden is an increasingly recognized concept, stemming from 
the rising tide of polypharmacy, which may impact on patient behaviors, including nonadherence. 
No instruments currently exist which specifically measure medicine-related burden. The Living 
with Medicines Questionnaire (LMQ) was developed for this purpose.
Objective: This study validated the LMQ in a sample of adults using regular prescription 
medicines in the UK.
Methods: Questionnaires were distributed in community pharmacies and public places in 
southeast England or online through UK health websites and social media. A total of 1,177 were 
returned: 507 (43.1%) from pharmacy distribution and 670 (56.9%) online. Construct validity was 
assessed by principal components analysis and item reduction undertaken on the original 60-item 
pool. Known-groups analysis assessed differences in mean total scores between participants 
using different numbers of medicines and between those who did or did not require assistance 
with medicine use. Internal consistency was assessed by Cronbach’s alpha. Free-text comments 
were analyzed thematically to substantiate underlying dimensions.
Results: A 42-item, eight-factor structure comprising intercorrelated dimensions (patient–
doctor relationships and communication about medicines, patient–pharmacist communication 
about medicines, interferences with daily life, practical difficulties, effectiveness, acceptance of 
medicine use, autonomy/control over medicines and concerns about medicine use) was derived, 
which explained 57.4% of the total variation. Six of the eight subscales had acceptable internal 
consistency (A0.7). More positive experiences were observed among patients using eight or 
fewer medicines compared to nine or more, and those independent with managing/using their 
medicines versus those requiring assistance. Free-text comments, provided by almost a third 
of the respondents, supported the domains identified.
Conclusion: The resultant LMQ-2 is a valid and reliable multidimensional measure of prescrip-
tion medicine use experiences, which covers more diverse domains than existing questionnaires. 
However, further validation work is necessary.
Keywords: medicines, polypharmacy, patient experience, questionnaire, validation
Introduction
Polypharmacy is increasing worldwide,1–3 driven by disease-specific clinical guidelines 
and specialist care, and has been recognized by policy makers in England as a problem 
to be addressed.4,5 This increasing tide of prescribing, frequently involving prophylactic 
drugs for secondary prevention, is clearly becoming burdensome to some patients.6–8 
The need to use long-term medicines engenders a mix of emotions, frequently combin-
ing gratitude for the potential benefits with anxiety about adverse effects and general 
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skepticism about net gain.9 Numerous studies in different 
countries show that most patients would prefer not to take 
medicines, particularly those with chronic conditions, that 
some patients are resistant toward using medicines10 and 
that there is a desire among some to stop some or all of their 
medicines.11 However, these perceptions and views may 
not always be taken into account during consultations about 
treatment, or incorporated into research studies, despite the 
increasing emphasis placed on patient perspectives of health 
outcomes both in practice and in research.
Recent policy documents in the UK seek to promote strat-
egies for optimizing the growing problem of polypharmacy 
in individual patients,4,5,12 but in order to determine which 
patients are most likely to benefit from interventions and to 
evaluate the interventions themselves, a patient-centered 
measure of experiences of multiple medicine use is needed.
A number of instruments exist which seek to measure 
satisfaction with medicines13,14 and the overall impact of 
using medicines on quality of life.15 The long-term use of 
medicines is, however, multidimensional and complex; any 
individual can experience both positive and negative aspects 
of medicine use.16–18 No existing instrument covers all issues 
that patients describe in their varied experiences of using 
medicines.19 A recently developed generic measure of treat-
ment burden, defined as “the impact of health care on patients’ 
functioning and well-being”, exists,20 which includes, but is 
not specific to, the burden of prescription medicine use. 
A number of disease-specific measures of treatment burden 
mostly assess the workload of self-managing diabetes and 
are not applicable to other long-term conditions.21 Medicine-
related burden is a relatively new concept, which a recent 
metasynthesis of qualitative studies suggests impacts on 
behaviors, including nonadherence.18 In addition to side 
effects and potential adverse events, medicine burden 
includes practical difficulties (such as opening packaging), 
challenges with managing complex regimes, psychosocial 
issues, particularly social stigma, disruptions to daily living 
and health system burden associated with regular medicine 
use, the latter including both patient–provider communication 
and information burden.18,22 Hence, any instrument purport-
ing to measure medicine burden must cover these issues. 
Medicine characteristics and prescribing regimens may all 
affect burden, for example, number of medicines, formula-
tions, route of administration, complex dosage regimens and 
generic brand switching.18
The Living with Medicines Questionnaire (LMQ; Supple-
mentary material) was developed for the specific purpose of 
measuring overall medicines burden.22 The instrument was 
based on the findings from interviews with 21 patients of 
different ages who were taking a diverse range of long-term 
multiple medicines,23 and covered the range of issues outlined 
above. Both initial item generation and content validation 
involved patients, unlike many instruments purporting to 
represent patient views.19 Preliminary testing of the LMQ 
involved patients taking long-term medicines recruited from 
an English primary care setting.22 This instrument included 60 
statements (items), accompanied by a five-point Likert-type 
scale (strongly agree to strongly disagree) plus a free-text 
open question. Results suggested that a larger sample was 
required to enable further psychometric testing and to reduce 
the number of items into a more manageable instrument. We 
describe here the results of psychometric testing and further 
development of this instrument.
Methods
Study population
Members of the general public were targeted for this study, 
as the proportion of people using long-term medicines in 
England is high (50%)1 and it enabled us to reach a diverse 
population. Ethics approval was granted by Medway School 
of Pharmacy Research Ethics Committee.
The inclusion criteria were adults, using regular prescrip-
tion medicines and living in the UK. All potential participants 
were provided with information about the study’s purpose 
and informed that consent was implied by completion and 
return of the questionnaire. Those interested were required to 
answer screening questions to ensure they met the inclusion 
criteria before completing the instrument.
Questionnaire distribution
A mixed-methods approach was used to maximize both 
response rates and diversity of demographic characteristics. 
The two main methods of distribution were 1) paper question-
naires distributed to both the general public using street inter-
cept and to community pharmacy users in southeast England 
and 2) an online survey available to the UK general public 
recruited through social media and health websites. Street 
surveys yield wide, representative, sociodemographic pro-
files, in terms of age, education or employment and are also 
a cost-effective distribution method for paper surveys,24,25 
while distribution to community pharmacy users increases 
the likelihood of reaching the people using long-term medi-
cines. The online survey was utilized to reach people from 
a wider geographic distribution, including the housebound, 
but is more likely to reach those with higher education and 
socioeconomic status.




Validation of the Living with Medicines Questionnaire (LMQ-2)
Recipients of paper questionnaires were given freepost 
envelopes for return. Online survey responses were down-
loaded from the provider website (Qualtrics®).
Data analysis
Data were managed and analyzed using IBM Statistical 
Package for the Social Sciences (version 22). Two databases 
were set up to handle paper and online surveys separately, 
then checked for errors and merged for analysis. Any signifi-
cant differences in participant characteristics were examined 
using chi-squared tests. The 60-item pool had 34 positively 
phrased and 26 negatively phrased statements. Reverse 
scoring enabled uniformity in the direction of responses, 
such that higher scores depicted negative experiences with 
medicine use.
Principal components analysis (PCA)
The correlation matrix was examined for item intercorrela-
tions, and Kaiser–Meyer–Olkin measure of sampling adequacy 
(acceptable values 0.6) and Bartlett’s test of sphericity 
(acceptable if P-value 0.05) were computed to ensure the 
data were suitable for factor analysis.26 PCA was conducted 
on the combined dataset using oblique rotation techniques 
(promax), assuming intercorrelations among underlying com-
ponents (factors), to ascertain the dimensional structure of the 
instrument. Scree plots (of eigenvalues and their associated 
number of components), and Kaiser’s rule (retain only factors 
with eigenvalue 1) were used to assess questionnaire dimen-
sionality. In addition, parallel analysis with Monte Carlo PCA 
was used to confirm the number of appropriate factors.27 We 
then reviewed the remaining items for potential floor or ceil-
ing effects (ie, items with 50% of answers concentrated in 
the first or last answer category) and examined item skewness 
and kurtosis (acceptable values 1.0).
Reliability analysis
Internal consistency was evaluated using Cronbach’s alpha 
(acceptable values 0.7), and changes in alpha following 
deletion of individual items from subscales were used to 
further inform decisions on item reduction/retention.
Known-groups validity
Known-groups analysis compared mean total LMQ-2 scores 
(for the 42-item version) between subsets of participants 
predicted to experience different degrees of burden, relating 
to the numbers of medicines used and whether assistance with 
managing medicines was required. Independent sample 
t-tests and one-way analysis of variance, involving only those 
respondents who completed all the LMQ items, were used for 
this analysis as LMQ-2 scores were normally distributed.
Responses to open question
The free-text comments box allowed respondents to add any 
other views about how medicines affected their day-to-day 
life in order to determine whether any outstanding major 
issues arose not covered by the instrument. Responses were 
analyzed thematically using the eight themes identified in 
the patient interviews, from which the original item pool 
was derived23 as an additional measure of the validity of the 
instrument.
Results
A total of 507 responses were obtained using paper question-
naires (45.6% of all those meeting the inclusion criteria), 
with more than half the respondents having been recruited 
from community pharmacies (60.5%, n307). A total of 670 
participants completed the online survey (68.4% of those 
accessing the survey link) through health websites (38.2%, 
n374) and social media (30.2%, n296). Overall, 544 
questionnaires were fully completed on the original 60-item 
pool, and the overall item-level response rates were over 
90%. Most items had skewness and kurtosis statistics 1.0, 
suggesting a tendency to univariate normality of the dataset. 
Raw mean scores on all items ranged from 2.13o1.02 to 
4.60o0.71. Only 5 of 60 items had skewness and kurtosis 
statistics 1 in absolute value, and one item had 68.5% of 
responses at the ceiling.
Participant characteristics
More females completed both paper (62.1%) and online 
(81.6%) surveys than males (P0.001), with the overall age 
of participants ranging from 18 to 90 years (Table 1). Younger 
respondents (65 years) and those with college/further educa-
tion mostly completed the online survey, whereas more people 
aged 65 and above returned the paper survey (P0.001). 
Overall, most participants (80.4%, n992) used up to and 
including eight prescription medicines, 113 (9.7%) needed 
assistance with using their medicines and 326 (27.9%) paid 
for their National Health Service prescription medicines.
Results of the PCA
A total of 544 fully completed responses (listwise deletion of 
missing data) were subjected to PCA. The Kaiser–Meyer–Olkin 
statistic (0.888) was satisfactory (0.6) and the Bartlett’s 
test of sphericity was significant (chi-square 9,788.903, 
degrees of freedom 861, P0.001); thus, the data met the 





necessary criteria for factor analysis. Moreover, interitem 
correlation coefficients showed no evidence of multicol-
linearity (r0.8),28 which also encouraged PCA. The initial 
solution resolved into 14 components with eigenvalues 1.0, 
explaining 61.1% of the total variation. Inspection of the 
scree plot revealed two breaks at the fifth and ninth compo-
nents (Figure 1).
Parallel analysis (Monte Carlo PCA) confirmed eight 
components with observed eigenvalues exceeding the 
criterion values (Table 2). PCA was re-run and the number of 
components fixed to eight. The resulting eight-factor solution 
explained 57.4% of the total variation and was conceptually 
interpretable (Table 3).
Item reduction and factor structure
Items with factor loadings 0.4 and/or cross loadings 
of 0.32 on at least two factors were deleted, based upon 
professional judgment that they did not fit well in underlying 
domains. This resulted in removal of 18 items (n18) from 
the original item pool, leaving 42 items. Five items with 
ceiling effects were retained as their factor loadings exceeded 
the minimum threshold for item retention (0.4), and were 
also judged as conceptually relevant.
Table 3 shows the 42-item factor structure. Emerging 
factors were interpreted as: patient–doctor relationships 
and communication about medicines (9 items), interfer-
ences with daily life (8 items), practicalities (7 items), 
effectiveness (4 items), patient–pharmacist communication 
about medicines (3 items), acceptance of medicine use 
(4 items), autonomy/control over medicine use (4 items) and 
concerns about potential harm (3 items). Most subscales have 
acceptable internal consistency (Cronbach’s alpha range, 
0.592–0.887).
All factor intercorrelations were 0.8 (range 0.099–
0.711), suggesting minimal redundancy among instru-
ment subscales, and thus possible discriminant validity.29 
Table 1 Characteristics of participants completing the survey







Female 306 (62.1) 542 (81.6) 848 (73.3)
Male 187 (37.9), n493 122 (18.4), n664 309 (26.7), n1,157
Age, years
1829 48 (9.7) 93 (13.9) 141 (12.1)
3049 98 (19.7) 258 (38.7) 356 (30.6)
5064 143 (28.8) 254 (38.1) 397 (34.1)
65 or over 208 (41.8), n497 62 (9.3), n667 270 (23.2), n1,164
Education level
Bachelor degree or higher 148 (30.5) 301 (45.2) 449 (39.0)
College level 140 (28.8) 258 (38.7) 398 (34.5)
Secondary level 145 (29.8) 93 (14.0) 238 (20.6)
Up to primary 53 (10.9), n486 14 (2.1), n666 67 (5.8), n1,152
Employment
Employed 176 (35.8) 324 (49.0) 500 (43.4)
Unemployed 74 (15.1) 182 (27.5) 256 (22.2)
Retired 241 (49.1), n491 155 (23.4), n661 396 (34.4), n1,152
Ethnicity
White 408 (83.8) 613 (93.4) 1,021 (89.3)
Asian/Chinese 27 (5.5) 28 (4.3) 55 (4.8)
African/Caribbean 44 (9.0) 6 (0.9) 50 (4.4)
Mixed 8 (1.6), n487 9 (1.4), n656 17 (1.5), n1,143
Number of medicines
14 261 (53.2) 302 (45.2) 563 (48.6)
58 176 (35.8) 253 (37.9) 429 (37.0)
9 54 (11.0), n491 113 (16.9), n668 167 (14.4), n1,159
Requires assistance with using medicines
No 453 (91.5) 596 (89.4) 1,049 (90.3)
Yes* 42 (8.5), n495 71 (10.6), n667 113 (9.7), n1,162
Pay for prescriptions
No 349 (71.7) 494 (72.0) 843 (72.1)
Yes 138 (28.3), n487 188 (27.4), n682 326 (27.9), n1,169
Note: *Carers included spouse/partner, relative, friends, nurse, support workers, support group.




Validation of the Living with Medicines Questionnaire (LMQ-2)
The strongest correlation was between perceived effective-
ness and patient–doctor relationships and communication 
about medicines (r0.711, P0.001; Table 4). Autonomy 
was negatively correlated with all other subscales, in par-
ticular, acceptance of medicine use (Table 4).
Known-groups validity
As hypothesized, the instrument was able to distinguish 
between participants using different numbers of medicines 
and between those who did or did not require assistance with 
medicine use. The mean LMQ-2 total score increased with 
the number of medicines used, and the medicine burden score 
for those requiring assistance was higher than for those who 
did not (Table 5).
Free-text comments
A total of 421 different comments were received, almost 
all of which supported the content domains. In particular, 
there were 76 comments describing the impact of using 
medicines, 71 describing medicine-related disruption to daily 
activities, 65 describing the impact of adverse effects on 
daily activities, personal life and socialization, 61 relating to 
efficacy or its lack and concerns about dependence on medi-
cines for symptom relief, performance of daily activities and 
prolonging life, 79 covering practical issues including desire 
for more suitable packaging and labeling, and information 
and 58 describing relationships with health professionals.
Discussion
This study reports the validation of the LMQ, a generic 
multidimensional questionnaire designed to encompass 
issues experienced by patients using long-term medicines, 
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Figure 1 Scree plot of the number of components (factors) in the Living with Medicines Questionnaire, showing two breaks at components 5 and 9, suggesting a 
multidimensional factor solution.







1 9.962 1.4519 Accept
2 4.036 1.4163 Accept
3 2.367 1.3878 Accept
4 2.076 1.3637 Accept
5 1.976 1.3412 Accept
6 1.724 1.3242 Accept
7 1.515 1.3055 Accept
8 1.389 1.2868 Accept
9 1.152 1.2686 Reject
10a 1.110 1.2526 Reject
Notes: *Generated randomly in 100 replications/simulations. aOnly 10 of 60 compo-
nents are shown in the table.





Table 3 Pattern matrix of the 42-item, eight-factor structure of the LMQ-2
LMQ-2 subscale/items Components
1 2 3 4 5 6 7 8
1. Patientdoctor relationships and communication about medicines (9 items, ]0.887)
Q53. My doctor(s) listen to my opinions and concerns about my medicines 0.887 0.012 0.123 0.062 0.080 0.030 0.094 0.044
Q22. The information my doctor(s) gives me about my medicines is useful 0.846 0.099 0.029 0.043 0.116 0.074 0.017 0.003
Q42. My doctor(s) spends enough time discussing my medicines with me 0.805 0.057 0.034 0.159 0.075 0.087 0.010 0.030
4,DPFRQÀGHQWVSHDNLQJWRP\GRFWRUVDERXWP\PHGLFLQHV 0.791 0.012 0.062 0.049 0.022 0.015 0.020 0.176
Q57. My doctor(s) takes my concerns about side effects seriously 0.728 0.054 0.155 0.183 0.142 0.037 0.053 0.091
Q21. I understand what my doctor(s) tell me about my medicines 0.658 0.037 0.044 0.171 0.197 0.119 0.087 0.082
Q50.  The health professionals providing my care know enough about me 
and my medicines
0.592 0.100 0.025 0.180 0.062 0.059 0.028 0.137
Q33. I trust the judgment of my doctor(s) in choosing medicines for me 0.542 0.001 0.031 0.314 0.015 0.159 0.129 0.001
Q45.  There is enough sharing of information about my medicines between 
the different health professionals providing my care
0.542 0.028 0.004 0.058 0.062 0.003 0.004 0.209
2. Interferences with daily life (8 items, ]0.838)
Q32. Taking medicines interferes with my social life 0.009 0.849 0.039 0.064 0.015 0.067 0.008 0.092
Q35.  Taking medicines causes me problems with daily tasks (such as work, 
housework)
0.048 0.820 0.089 0.091 0.046 0.037 0.035 0.047
Q60. The medicines I use have an adverse effect on the holidays I can take 0.052 0.730 0.012 0.177 0.005 0.006 0.019 0.150
Q29. My life revolves around using my medicines 0.120 0.698 0.052 0.181 0.022 0.317 0.100 0.143
Q37. Taking medicines affects my driving ability 0.002 0.686 0.110 0.029 0.040 0.026 0.122 0.077
Q34. I have to put a lot of planning and thought into taking my medicines 0.068 0.618 0.041 0.192 0.044 0.180 0.171 0.121
Q38. I worry that I have to take several medicines at the same time 0.140 0.592 0.087 0.059 0.073 0.046 0.047 0.135
Q56. Changes in daily routine cause problems with my medicines 0.024 0.558 0.105 0.214 0.070 0.009 0.136 0.188
3. Practicalities (7 items, ]0.708)
4,WLVGLIÀFXOWWRLGHQWLI\ZKLFKPHGLFLQHLVZKLFK 0.133 0.037 0.773 0.034 0.046 0.030 0.073 0.019
Q1. The instructions on my medicines are easy to follow 0.059 0.163 0.683 0.139 0.045 0.051 0.006 0.066
4,ÀQGRSHQLQJWKHSDFNDJLQJRIP\PHGLFLQHVGLIÀFXOW 0.048 0.002 0.640 0.017 0.062 0.052 0.109 0.002
4,ÀQGJHWWLQJP\SUHVFULSWLRQVIURPWKHGRFWRUGLIÀFXOW 0.244 0.064 0.635 0.087 0.163 0.043 0.192 0.121
4,ÀQGJHWWLQJP\PHGLFLQHVIURPWKHSKDUPDFLVWGLIÀFXOW 0.099 0.041 0.628 0.259 0.089 0.165 0.175 0.146
4,ÀQGXVLQJP\PHGLFLQHVGLIÀFXOW 0.027 0.295 0.465 0.087 0.040 0.208 0.134 0.019
Q8. It is easy to keep to my medicines routine 0.027 0.083 0.400 0.049 0.009 0.221 0.011 0.116
4. Effectiveness (4 items, ]0.796)
4,DPVDWLVÀHGZLWKWKHHIIHFWLYHQHVVRIP\PHGLFLQHV 0.066 0.037 0.161 0.698 0.102 0.051 0.041 0.129
Q30. My medicines live up to my expectations 0.073 0.088 0.014 0.694 0.008 0.084 0.054 0.092
Q51. My medicines are working 0.090 0.007 0.060 0.685 0.019 0.008 0.181 0.137
Q31. My medicines prevent my condition getting worse 0.040 0.033 0.041 0.650 0.070 0.168 0.137 0.049
5. Patientpharmacist communication about medicines (3 items, ]0.877)
Q25. The information my pharmacist gives me about my medicines is useful 0.030 0.000 0.039 0.049 0.911 0.026 0.045 0.036
4,DPFRQÀGHQWVSHDNLQJWRP\SKDUPDFLVWDERXWP\PHGLFLQHV 0.034 0.030 0.055 0.037 0.879 0.002 0.041 0.027
Q24. I understand what my pharmacist tells me about my medicines 0.012 0.014 0.008 0.042 0.936 0.013 0.006 0.035
6. Acceptance of medicine use (4 items, ]0.592)
Q13. Taking medicines is routine for me 0.019 0.010 0.060 0.114 0.030 0.824 0.001 0.008
Q27. I accept that I have to take medicines long term 0.011 0.088 0.107 0.254 0.049 0.739 0.130 0.006
Q4. My medicines are important to me 0.084 0.232 0.097 0.083 0.053 0.494 0.068 0.093
Q28. My medicines allow me to live my life as I want to 0.050 0.185 0.045 0.278 0.098 0.483 0.102 0.037
7. Autonomy/control over medicine use (4 items, ]0.625)
Q54. I can vary the dose of the medicines I take 0.002 0.245 0.010 0.064 0.028 0.092 0.763 0.049
Q49. I can change the times I take my medicines if I want to 0.002 0.077 0.061 0.021 0.128 0.086 0.752 0.111
Q41. I can choose whether or not to take my medicines 0.034 0.103 0.115 0.106 0.035 0.301 0.592 0.043
Q52. I can adapt my medicine-taking to my lifestyle 0.038 0.106 0.037 0.194 0.004 0.050 0.592 0.029
8. Concerns about potential harm (3 items, ]0.751)
Q11. I am concerned about experiencing side effects 0.053 0.041 0.051 0.040 0.003 0.013 0.021 0.925
Q12.  I am concerned about possible damaging long-term effects of taking 
medicines
0.055 0.120 0.099 0.205 0.029 0.019 0.080 0.902
Q40. I worry that my medicines may interact with each other 0.053 0.329 0.163 0.011 0.068 0.061 0.048 0.421
Notes: Extraction method: principal component analysis. Rotation method: promax with Kaiser normalization. ACronbachs alpha. The numbers in bold represent 
VXEVWDQWLYHIDFWRUORDGLQJVDERYHVKRZLQJLWHPVWKDWDUHDGHTXDWHO\DVVRFLDWHGZLWKDVSHFLÀFGRPDLQVXEVFDOHRIWKH/04
Abbreviations: LMQ, Living with Medicines Questionnaire; Q, question.




Validation of the Living with Medicines Questionnaire (LMQ-2)
LMQ was shown to cover more domains than most other 
instruments purporting to describe patient experiences of 
medicine use.19 The instrument covers eight interrelated, 
yet distinct, dimensions of the medicine use experience: 
perceptions about effectiveness, concerns about medicine 
use, patient–provider relationships and communication about 
medicines, practical difficulties, interferences with daily life, 
autonomy/control over medicine and acceptance of medicine 
use, which have been cited by users of long-term medicines 
as burdensome.18 These dimensions match well to both 
the domains identified from qualitative research on which 
the instrument was originally based and with subsequent 
literature.18,19 Additional comments added by questionnaire 
respondents also support these domains. We believe they all 
relate to an overarching construct of medicine burden, for 
which no measure currently exists.
Perceptions of efficacy and concerns about the negative 
effects of medicines are widely reported in the literature, with 
most patients weighing benefits from medicines against any 
associated burden, perhaps enduring inconveniences associ-
ated with their use while reluctantly accepting the need for 
treatment.18,30,31 Patients’ perceptions concerning the desired 
therapeutic outcome influence both attitudes and behaviors 
toward medicine.32,33 Concerns about potential harm from 
side effects, long-term use and/or dependency are common.10 
Relationships with health professionals supplying medicines 
and information sharing may influence both commitment 
to taking medicines and perceptions of effectiveness,31 
with poor relationships and communication becoming 
burdensome to some individuals due to consultation styles, 
amount of information provided, conflicting information 
and lack of continuity of care.34,35 Observational research 
shows that overall treatment burden may be compounded by 
patients’ experiences of medicine use being neglected during 
consultations.36 Practical difficulties with the long-term use of 
medicines have been documented as burdensome,37–39 while 
the burden of managing medicine routines has been reported 
as demanding of both time and resources.8,18 There is also 
evidence that many patients manipulate their medicine regi-
mens, especially when they experience unbearable burden, 
perceive their medicines as inappropriate or are dissatisfied 
with their medicine.33,40–42 Conversely, regimens which 
are inconvenient may lead to perceived lack of control or 
autonomy. The autonomy subscale was highly negatively 
correlated with acceptance of medicine use, suggesting that 
such acceptance may be associated with perceived inability to 
modify regimens. This, together with experiences of adverse 
effects, may add to the overall burden through interfering 
with daily activities.18 Indeed, our data support this, with 
the domain of practicalities being positively correlated with 
interference, but also negatively correlated with autonomy. 
Negative correlations were also found between autonomy and 
communication with both doctors and pharmacists, which 
may suggest a reluctance to go against the advice/directions 
of health care professionals.
The eight subscales of the LMQ-2 are valid and reliable. 
The generic nature of this questionnaire contributes to its 
potential usefulness in identifying a wide range of issues 
Table 4 Intercorrelations among the LMQ-2 subscales
Subscale Doctor Interfrnc Practical Effectiv Pharm Accept Auto Concern
Doctor 0.241** 0.506** 0.711* 0.616** 0.319* 0.189* 0.201*
Interfrnc 0.502** 0.356** 0.254** 0.032 0.029 0.406*
Practical 0.511* 0.507** 0.256** 0.242* 0.190*
Effectiv 0.574** 0.534* 0.148 0.317**
Pharm 0.269* 0.156* 0.099 




Abbreviations: accept, acceptance of medicine use; auto, autonomy/control over medicine; concern, concerns about potential harm; doctor, patientdoctor relationships 
and communication about medicines; effectiv, effectiveness; Interfrnc, interferences with daily life; LMQ, Living with Medicines Questionnaire; pharm, patientpharmacist 
communication about medicines; practical, practicalities.
Table 5 Known-groups validity of the LMQ-2
Category Number of 
participants 
per subgroup
Total LMQ-2 score 





9 69 106.2o22.0 (P0.001)
Assisted with medicine use
No 490 99.0o18.2
Yes 44 105.5o20.2 (P0.026)
Abbreviation: LMQ, Living with Medicines Questionnaire.





arising from medicine use either in single conditions or in 
patients with multimorbidity. Preliminary evidence of the 
measure’s discriminant validity is promising, with the data 
showing that using a higher number of medicines and need-
ing assistance with medicines were significantly associated 
with more medicine burden.
Strengths, limitations and future work
The LMQ looks promising as a patient-reported measure of 
the burden of using long-term medicines. Item-level response 
rates were generally high, potentially indicating interest in 
the medicine-related issues covered in the questionnaire. 
Unlike many instruments reported in the literature, the devel-
opment and validation of the LMQ were founded on patient-
generated data from representative patient populations.
Elimination of poorly performing items, using psychome-
trically sound criteria and an adequate sample size recruited 
from demographically diverse settings, resulted in a revised 
instrument, the LMQ-2. However, the item reduction process 
may have led to loss of potentially important items. Side 
effects did not emerge as a separate domain, instead merg-
ing with concerns about potential harm, but generated a 
significant number of free-text comments. No significant 
ceiling effects were apparent, in contrast to measures of 
treatment satisfaction.13 The reliability of the LMQ-2 sub-
scales may be strengthened by use of both negatively and 
positively phrased statements and the intermixed ordering 
of items across different content domains. Methodological 
studies suggest that grouping questionnaire items into their 
hypothetical domains, a common occurrence in existing 
medicine-related measures, may artificially inflate internal 
consistency.43 Potential obsequiousness bias, a common 
methodological problem with self-report measures, was 
minimized by the use of different self-report methods (paper 
and online), encouraging completion outside of standard 
health facilities, in diverse public settings.
Further development work is necessary to assess criterion-
related validity by comparison with existing measures of the 
medicine use experience. Our samples were insufficiently 
large to assess whether the different distribution methods 
resulted in any differences in the instrument’s psychometric 
properties. Moreover, confirmatory factor analysis was not 
undertaken. Thus, further work is required with larger sample 
sizes to enable these analyses. Cross-cultural adaptations 
may be needed to support the instrument’s usability in other 
populations. Future studies may also involve adaptations of 
the LMQ (or its subscales) for use in specific disease condi-
tions or patient populations.
Conclusion
The LMQ-2 is a valid and reliable multidimensional measure 
of adult patients’ experiences of prescription medicine use. 
Although further work on the instrument is desirable, the 
findings reported here are promising and suggest the instru-
ment may be useful in measuring medicine-related burden, 
currently a neglected aspect of the assessment of health care 
interventions.
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